Serum levels of CXCL9 emerge as an interesting biomarker for increased IFNγ activity (62) and may be particularly helpful when considering the use of emapalumab in first-line treatment of HLH in the context of other inborn errors of immunity. This evidence concerns the gene IFNG and hemophagocytic syndrome.